Sun Pharma approved to sell Ozempic generic in SA
India’s Sun Pharmaceutical Industries has received approval from South Africa’s health regulator to manufacture and sell a generic version of semaglutide, the active ingredient in Novo Nordisk’s diabetes and obesity medicines.
The South African Health Products Regulatory Authority (SAHPRA) has approved Sun Pharma’s generic semaglutide injection for adults with inadequately controlled type 2 diabetes.
The entry of generic products is also expected to increase competition for Eli Lilly, which markets its diabetes and obesity medicines in South Africa.
This is a summary of the original articles listed below. Always read the source articles for the full context. GhanaSummary does not create or modify the news — we summarise and link to original publishers.
